Prognostic value of the pretreatment serum level of cytokeratin fraction 21‐1 in undifferentiated nasopharyngeal carcinoma: A study of 332 cases

Wei, Zhengbo; Zeng, Xiaoqun; Xu, Jianping; Xu-wei, Duan; Yang, Jianbo; Xie, Ying

doi:10.1002/hed.23261

Cited by 8 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the stage, CYFRA21-1 could be the most important prognostic factor in predicting the outcomes of patients with malignant tumors, and the serum level of CYFRA21-1 could be used as a powerful prognostic marker in NPC. Wei et al [22] demonstrated that the pretreatment serum level of CYFRA21-1 could be a reliable biomarker for evaluating the long-term prognosis of patients with undifferentiated NPC. In our study, the relationship between the clinical objective tumor response and serum CYFRA21-1 change in patients submitted to systemic clinical treatment was synchronized.…”

Section: Discussionmentioning

confidence: 99%

Serum CYFRA21-1 as an effective tumor biomarker for patients with nasopharyngeal carcinoma

Song¹,

WANG²,

WANG³

et al. 2015

neo

View full text Add to dashboard Cite

We investigated if the serum cytokeratin 19 fragment 21.1 (CYFRA21-1) level was elevated in nasopharyngeal carcinoma (NPC) and can function as a biomarker for detection and monitoring of NPC. Three hundred and one study subjects were divided into two groups: the NPC group (n=126) and healthy control group (n=175). Serum CYFRA21-1 levels were measured before and after treatment using a chemiluminescent immunoassay, and its association with tumor stage and the clinical objective responses were analyzed. Receiver operating characteristic (ROC) curve analysis was performed to discriminate patients with NPC from the healthy controls. The pretreatment serum CYFRA21-1 level was significantly elevated in patients with NPC compared with the healthy controls (5.07±1.98 ng/ml vs 2.36±1.21 ng/ml, p<0.001), and it declined significantly after the entire treatment (2.14±0.72 ng/ml, p<0.001). The serum CYFRA21-1 level of patients with a classification of T3-4 was significantly higher than that of those with class T1-2 (5.64±2.23 ng/ml vs 4.62±1.64 ng/ml, p=0.006), and that of patients with clinical stage III-IV was higher than clinical stage I-II (5.31±2.02 vs 4.04±1.37 ng/ml, p=0.003). The AUC, sensitivity and specificity of elevated serum CYFRA21-1 in patients with NPC was 0.91, 0.83 and 0.89 respectively. In conclusion, the serum CYFRA21-1 level could be a reliable and effective biomarker for the detection and monitoring of NPC tumor progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum CYFRA21-1 as an effective tumor biomarker for patients with nasopharyngeal carcinoma

Song¹,

WANG²,

WANG³

et al. 2015

neo

View full text Add to dashboard Cite

show abstract

“…It is especially common in Guangdong, Guangxi, and other regions in China, and its incidence rate is as high as 20-30/100,000 per year. 1 Epidemiological and experimental studies have shown that genetic susceptibility, Epstein–Barr virus (EBV) infection, and environmental factors are specific and multifactorial causes of NPC. 2 Although many people are exposed to EBV infection and ecological risk factors, including heavy smoking and alcohol consumption, only a small proportion of the population has developed NPC, indicating that individual genetic susceptibility may play a more important role in the carcinogenic mechanism of NPC.…”

Section: Introductionmentioning

confidence: 99%

The Relationship Between the hOGG1 rs1052133 Polymorphism and the Occurrence of Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis

Li,

Yao,

Zhang

et al. 2024

Technol Cancer Res Treat

View full text Add to dashboard Cite

Objectives: Exploring the relationship between the hOGG1 rs1052133 polymorphism and the occurrence of nasopharyngeal carcinoma (NPC). Methods: PubMed, Web of Science, Scopus, CNKI, Wanfangdata, and VIP were used to search for studies and the NOS evaluation scale was used to evaluate the quality. All studies were grouped according to different genotypes. The Cochrane's Q test and I2 test were used for heterogeneity evaluations. If heterogeneity was small, the fixed effects model was used, and conversely, the random effects model was used. Publication bias was also detected. P < .05 in all results indicated statistically significant. Results: We ultimately included 6 studies with 2021 NPC patients in the study group and 2375 healthy populations in the control group. After meta-analysis, it was found that the total OR value of the “Ser/Cys (CG) vs Ser/Ser (CC)” group was 1.00 (95% CI: 0.85-1.18) and the “Cys/Cys (GG) vs Ser/Ser (CC)” group was 1.06 (95% CI: 0.87-1.28). These results were not statistically significant (P > .05). Furthermore, the integrated total OR values of each group were not statistically significant with or without the smoking history, even in other genotype models (Allele, Dominant, Recessive, and Additive) (P > .05). Conclusion: There is no clear correlation between the hOGG1 rs1052133 polymorphism and the occurrence of NPC, even with or without the smoking history.

show abstract

“…In these areas, its incidence is up to 20–30/100,000 per year. 1 Mechanisms of NPC onset and progression remain unknown, though they are thought to be related to genomic DNA damage, as in many other malignant tumors. 2 , 3 Oxidative DNA damage is one of the most frequent causes of malignant tumors, and 7,8-dihydro-8-oxoguanine is one of the best characterized oxidative DNA lesions.…”

Section: Introductionmentioning

confidence: 99%

Association of polymorphisms hOGG1 rs1052133 and hMUTYH rs3219472 with risk of nasopharyngeal carcinoma in a Chinese population

Xie

Zhou

et al. 2016

OTT

Self Cite

View full text Add to dashboard Cite

This case–control study investigates the possible relationships between the single-nucleotide polymorphisms rs1052133 in the human 8-oxoguanine DNA glycosylase 1 (hOGG1) gene and rs3219472 in the human MutY glycosylase homologue (hMUTYH) gene and the risk of nasopharyngeal carcinoma (NPC). The two polymorphisms were genotyped in 488 unrelated NPC patients and 573 cancer-free controls. Genotype GG at rs1052133 was associated with significantly lower NPC risk than genotypes GC + CC (odds ratio [OR] 0.770, 95% confidence interval [CI] 0.595–0.996, P=0.012). In subgroup analyses, subjects with genotype GG at rs1052133 were at lower risk of NPC than those with GC or CC among individuals older than 40 years (OR 0.706, 95% CI 0.524–0.950), women (OR 0.571, 95% CI 0.337–0.968), and those with no smoking history (OR 0.634, 95% CI 0.463–0.868). No significant association was seen between polymorphisms at hMUTYH rs3219472 and the risk of NPC. However, gene–gene interaction analysis showed that subjects with genotype CC at rs1052133 and genotype AA at rs3219472 (CC/AA) were at 2.887-fold higher risk of NPC than those with GG/GG, 3.183-fold higher risk than those with GG/GA, and 3.392-fold higher risk than those with GG/AA. Our results suggest that hOGG1 rs1052133 polymorphism may play an important role in NPC pathogenesis, especially among women, >40 years old, and those with no smoking history. The hMUTYH rs3219472 polymorphism may interact with hOGG1 rs1052133 polymorphism to influence susceptibility to NPC.

show abstract

Prognostic value of the pretreatment serum level of cytokeratin fraction 21‐1 in undifferentiated nasopharyngeal carcinoma: A study of 332 cases

Abstract: The pretreatment serum level of CYFRA 21-1 would be a reliable biomarker to evaluate the long-term prognosis of patients with undifferentiated NPC.

Cited by 8 publications

References 21 publications

Serum CYFRA21-1 as an effective tumor biomarker for patients with nasopharyngeal carcinoma

Serum CYFRA21-1 as an effective tumor biomarker for patients with nasopharyngeal carcinoma

The Relationship Between the hOGG1 rs1052133 Polymorphism and the Occurrence of Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis

Association of polymorphisms hOGG1 rs1052133 and hMUTYH rs3219472 with risk of nasopharyngeal carcinoma in a Chinese population

Contact Info

Product

Resources

About